

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p>		<p>Complete if Known</p> <table border="1" style="width: 100%; border-collapse: collapse;"><tr><td style="width: 50%;">Application Number</td><td style="width: 50%;">New</td></tr><tr><td>Filing Date</td><td>Herewith</td></tr><tr><td>First Named Inventor</td><td>STEPHEN C. WARDLAW. et al</td></tr><tr><td>Group Art Unit</td><td>2863</td></tr><tr><td>Examiner Name</td><td>A. Bhat</td></tr><tr><td>Attorney Docket Number</td><td>5169-0011-1-1</td></tr></table>		Application Number	New	Filing Date	Herewith	First Named Inventor	STEPHEN C. WARDLAW. et al	Group Art Unit	2863	Examiner Name	A. Bhat	Attorney Docket Number	5169-0011-1-1
Application Number	New														
Filing Date	Herewith														
First Named Inventor	STEPHEN C. WARDLAW. et al														
Group Art Unit	2863														
Examiner Name	A. Bhat														
Attorney Docket Number	5169-0011-1-1														
Sheet	2	of	2												

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
M		Information on CLIA Waivers (Clinical Laboratory Improvement Amendments) pages 1-2	
M		CLIA Categorization Criteria, pages 1-2	
M		CLIA Home Page - Clinical Laboratory Improvement Amendments, pages 1-2	
		Guidance for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Criteria for Waiver; Draft Guidance for Industry and FDA Applications pages 1-22	

Examiner Signature		Date Considered	1/7/04
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

